Tokyo Tape
Sign in
← Suzuken

Quarterly report · Q1

9987.TEDINET S100OZ8T
Period2022-04-01 → 2022-06-30
Filed2022-08-12
StandardJapan GAAP
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 31
MetricValuePeriodScopeSource row
Revenue¥553.8bn2022-04-01 → 2022-06-30Cons.Net sales
Revenue¥2.24T2021-04-01 → 2022-03-31Cons.Net sales (5-year summary)
Revenue¥541.1bn2021-04-01 → 2021-06-30Cons.Net sales
Operating income¥3.5bn2022-04-01 → 2022-06-30Cons.Operating income
Operating income−¥1.6bn2021-04-01 → 2021-06-30Cons.Operating income
Ordinary income¥4.6bn2022-04-01 → 2022-06-30Cons.Ordinary income
Ordinary income¥23.4bn2021-04-01 → 2022-03-31Cons.Ordinary income loss (5-year summary)
Ordinary income−¥443m2021-04-01 → 2021-06-30Cons.Ordinary income
Profit before tax¥4.5bn2022-04-01 → 2022-06-30Cons.Income before income taxes
Profit before tax−¥479m2021-04-01 → 2021-06-30Cons.Income before income taxes
Net income (owners)¥2.7bn2022-04-01 → 2022-06-30Cons.Profit loss attributable to owners of parent
Net income (owners)¥14.4bn2021-04-01 → 2022-03-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)−¥414m2021-04-01 → 2021-06-30Cons.Profit loss attributable to owners of parent
Net income¥2.7bn2022-04-01 → 2022-06-30Cons.Profit loss
Net income−¥373m2021-04-01 → 2021-06-30Cons.Profit loss
Total assets¥1.17Tat 2022-06-30Cons.Assets
Total assets¥1.14Tat 2022-03-31Cons.Assets
Total assets¥1.17Tat 2021-06-30Cons.Total assets (5-year summary)
Total liabilities¥745.8bnat 2022-06-30Cons.Liabilities
Total liabilities¥723.7bnat 2022-03-31Cons.Liabilities
Net assets / equity¥419.3bnat 2022-06-30Cons.Net assets
Net assets / equity¥418.1bnat 2022-03-31Cons.Net assets
Net assets / equity¥415.3bnat 2021-06-30Cons.Net assets (5-year summary)
Cash and deposits¥132.1bnat 2022-06-30Cons.Cash and deposits
Cash and deposits¥141.4bnat 2022-03-31Cons.Cash and deposits
EPS (basic)¥30.492022-04-01 → 2022-06-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥163.192021-04-01 → 2022-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-4.662021-04-01 → 2021-06-30Cons.Basic earnings loss per share (5-year summary)
Equity ratio36.0%at 2022-06-30Cons.Equity to asset ratio (5-year summary)
Equity ratio36.6%at 2022-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio35.4%at 2021-06-30Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 40
SegmentItemPeriodValue
jpcrp040300-q1r_E02780-000The Healthcare Related Services Businessreportable segmentrevenue2022-04-01 → 2022-06-30¥52.6bn
jpcrp040300-q1r_E02780-000The Healthcare Related Services Businessreportable segmentrevenue external2022-04-01 → 2022-06-30¥9.8bn
jpcrp040300-q1r_E02780-000The Healthcare Related Services Businessreportable segmentrevenue intersegment2022-04-01 → 2022-06-30¥42.8bn
jpcrp040300-q1r_E02780-000The Healthcare Related Services Businessreportable segmentsegment profit2022-04-01 → 2022-06-30¥434m
jpcrp040300-q1r_E02780-000The Insurance Pharmacy Businessreportable segmentrevenue2022-04-01 → 2022-06-30¥21.4bn
jpcrp040300-q1r_E02780-000The Insurance Pharmacy Businessreportable segmentrevenue external2022-04-01 → 2022-06-30¥21.4bn
jpcrp040300-q1r_E02780-000The Insurance Pharmacy Businessreportable segmentrevenue intersegment2022-04-01 → 2022-06-30¥1m
jpcrp040300-q1r_E02780-000The Insurance Pharmacy Businessreportable segmentsegment profit2022-04-01 → 2022-06-30¥31m
jpcrp040300-q1r_E02780-000The Pharmaceutical Distribution Businessreportable segmentrevenue2022-04-01 → 2022-06-30¥533.5bn
jpcrp040300-q1r_E02780-000The Pharmaceutical Distribution Businessreportable segmentrevenue external2022-04-01 → 2022-06-30¥519.6bn
jpcrp040300-q1r_E02780-000The Pharmaceutical Distribution Businessreportable segmentrevenue intersegment2022-04-01 → 2022-06-30¥13.8bn
jpcrp040300-q1r_E02780-000The Pharmaceutical Distribution Businessreportable segmentsegment profit2022-04-01 → 2022-06-30¥2.4bn
jpcrp040300-q1r_E02780-000The Pharmaceutical Manufacturing Businessreportable segmentrevenue2022-04-01 → 2022-06-30¥11.5bn
jpcrp040300-q1r_E02780-000The Pharmaceutical Manufacturing Businessreportable segmentrevenue external2022-04-01 → 2022-06-30¥2.9bn
jpcrp040300-q1r_E02780-000The Pharmaceutical Manufacturing Businessreportable segmentrevenue intersegment2022-04-01 → 2022-06-30¥8.6bn
jpcrp040300-q1r_E02780-000The Pharmaceutical Manufacturing Businessreportable segmentsegment profit2022-04-01 → 2022-06-30¥587m
Total Of Reportable Segments And Otherssegment totalrevenue2022-04-01 → 2022-06-30¥618.9bn
Total Of Reportable Segments And Otherssegment totalrevenue external2022-04-01 → 2022-06-30¥553.8bn
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2022-04-01 → 2022-06-30¥65.2bn
Total Of Reportable Segments And Otherssegment totalsegment profit2022-04-01 → 2022-06-30¥3.5bn
jpcrp040300-q1r_E02780-000The Healthcare Related Services Businessreportable segmentrevenue2021-04-01 → 2021-06-30¥41.9bn
jpcrp040300-q1r_E02780-000The Healthcare Related Services Businessreportable segmentrevenue external2021-04-01 → 2021-06-30¥9.8bn
jpcrp040300-q1r_E02780-000The Healthcare Related Services Businessreportable segmentrevenue intersegment2021-04-01 → 2021-06-30¥32.1bn
jpcrp040300-q1r_E02780-000The Healthcare Related Services Businessreportable segmentsegment profit2021-04-01 → 2021-06-30¥644m
jpcrp040300-q1r_E02780-000The Insurance Pharmacy Businessreportable segmentrevenue2021-04-01 → 2021-06-30¥21.9bn
jpcrp040300-q1r_E02780-000The Insurance Pharmacy Businessreportable segmentrevenue external2021-04-01 → 2021-06-30¥21.9bn
jpcrp040300-q1r_E02780-000The Insurance Pharmacy Businessreportable segmentrevenue intersegment2021-04-01 → 2021-06-30¥5m
jpcrp040300-q1r_E02780-000The Insurance Pharmacy Businessreportable segmentsegment profit2021-04-01 → 2021-06-30¥323m
jpcrp040300-q1r_E02780-000The Pharmaceutical Distribution Businessreportable segmentrevenue2021-04-01 → 2021-06-30¥520.1bn
jpcrp040300-q1r_E02780-000The Pharmaceutical Distribution Businessreportable segmentrevenue external2021-04-01 → 2021-06-30¥506.1bn
jpcrp040300-q1r_E02780-000The Pharmaceutical Distribution Businessreportable segmentrevenue intersegment2021-04-01 → 2021-06-30¥13.9bn
jpcrp040300-q1r_E02780-000The Pharmaceutical Distribution Businessreportable segmentsegment profit2021-04-01 → 2021-06-30−¥3.2bn
jpcrp040300-q1r_E02780-000The Pharmaceutical Manufacturing Businessreportable segmentrevenue2021-04-01 → 2021-06-30¥11.3bn
jpcrp040300-q1r_E02780-000The Pharmaceutical Manufacturing Businessreportable segmentrevenue external2021-04-01 → 2021-06-30¥3.3bn
jpcrp040300-q1r_E02780-000The Pharmaceutical Manufacturing Businessreportable segmentrevenue intersegment2021-04-01 → 2021-06-30¥7.9bn
jpcrp040300-q1r_E02780-000The Pharmaceutical Manufacturing Businessreportable segmentsegment profit2021-04-01 → 2021-06-30¥468m
Total Of Reportable Segments And Otherssegment totalrevenue2021-04-01 → 2021-06-30¥595.1bn
Total Of Reportable Segments And Otherssegment totalrevenue external2021-04-01 → 2021-06-30¥541.1bn
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2021-04-01 → 2021-06-30¥54.0bn
Total Of Reportable Segments And Otherssegment totalsegment profit2021-04-01 → 2021-06-30−¥1.7bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 350
ItemContextValueUnit
Provision for loss on anti monopoly act clCurrentQuarterInstant5475000000JPY
Other clPrior1YearInstant15120000000JPY
Other clCurrentQuarterInstant41719000000JPY
Current liabilitiesPrior1YearInstant697879000000JPY
Current liabilitiesCurrentQuarterInstant719899000000JPY
Provision for directors retirement benefitsPrior1YearInstant26000000JPY
Provision for directors retirement benefitsCurrentQuarterInstant－JPY
Net defined benefit liabilityPrior1YearInstant2310000000JPY
Net defined benefit liabilityCurrentQuarterInstant2361000000JPY
Other nclPrior1YearInstant23439000000JPY
Other nclCurrentQuarterInstant23520000000JPY
Noncurrent liabilitiesPrior1YearInstant25776000000JPY
Noncurrent liabilitiesCurrentQuarterInstant25881000000JPY
LiabilitiesPrior1YearInstant723655000000JPY
LiabilitiesCurrentQuarterInstant745781000000JPY
Capital stockPrior1YearInstant13546000000JPY
Capital stockCurrentQuarterInstant13546000000JPY
Capital surplusPrior1YearInstant39337000000JPY
Capital surplusCurrentQuarterInstant39337000000JPY
Retained earningsPrior1YearInstant394296000000JPY
Retained earningsCurrentQuarterInstant393818000000JPY
Treasury stockPrior1YearInstant-61504000000JPY
Treasury stockCurrentQuarterInstant-61505000000JPY
Shareholders equityPrior1YearInstant385675000000JPY
Shareholders equityCurrentQuarterInstant385197000000JPY
Valuation difference on available for sale securitiesPrior1YearInstant34211000000JPY
Valuation difference on available for sale securitiesCurrentQuarterInstant35554000000JPY
Revaluation reserve for landPrior1YearInstant-4750000000JPY
Revaluation reserve for landCurrentQuarterInstant-4750000000JPY
Foreign currency translation adjustmentPrior1YearInstant662000000JPY
Foreign currency translation adjustmentCurrentQuarterInstant1181000000JPY
Remeasurements of defined benefit plansPrior1YearInstant1887000000JPY
Remeasurements of defined benefit plansCurrentQuarterInstant1750000000JPY
Valuation and translation adjustmentsPrior1YearInstant32011000000JPY
Valuation and translation adjustmentsCurrentQuarterInstant33737000000JPY
Non controlling interestsPrior1YearInstant375000000JPY
Non controlling interestsCurrentQuarterInstant368000000JPY
Net assetsPrior1YearInstant418062000000JPY
Net assetsCurrentQuarterInstant419302000000JPY
Liabilities and net assetsPrior1YearInstant1141717000000JPY
Liabilities and net assetsCurrentQuarterInstant1165084000000JPY
Net salesPrior1YTDDuration541102000000JPY
Net salesCurrentYTDDuration553754000000JPY
Cost of salesPrior1YTDDuration506963000000JPY
Cost of salesCurrentYTDDuration514816000000JPY
Gross profitPrior1YTDDuration34139000000JPY
Gross profitCurrentYTDDuration38937000000JPY
Selling general and administrative expensesPrior1YTDDuration35774000000JPY
Selling general and administrative expensesCurrentYTDDuration35387000000JPY
Operating incomePrior1YTDDuration-1635000000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 12 of 12 passed
balance sheet identityconsolidated 2022-03-31pass
balance sheet identityconsolidated 2022-06-30pass rounding
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2022-03-31pass
statement vs summary · net assetsconsolidated 2022-06-30pass
statement vs summary · net income attributable to parentconsolidated 2021-04-01/2021-06-30pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-06-30pass
statement vs summary · revenueconsolidated 2021-04-01/2021-06-30pass
statement vs summary · revenueconsolidated 2022-04-01/2022-06-30pass
statement vs summary · total assetsconsolidated 2022-03-31pass
statement vs summary · total assetsconsolidated 2022-06-30pass